• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tactile Systems Technology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/9/25 4:56:54 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care
    Get the next $TCMD alert in real time by email
    false 0001027838 TACTILE SYSTEMS TECHNOLOGY INC 0001027838 2025-05-07 2025-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  May 7, 2025

     

    TACTILE SYSTEMS TECHNOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37799   41-1801204
    (State or other jurisdiction of   (Commission   (IRS Employer
    incorporation)   File Number)   Identification No.)

     

    3701 Wayzata Blvd, Suite 300, Minneapolis, MN 55416

    (Address of principal executive offices) (Zip Code)

     

    (612) 355-5100

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which
    registered
    Common Stock, Par Value $0.001 Per Share TCMD The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  ¨ Emerging growth company

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

      

     

     

     

    Item 5.02.Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    As reported below in Item 5.07, on May 7, 2025, the stockholders of Tactile Systems Technology, Inc. (the “Company”) approved the Tactile Systems Technology, Inc. 2025 Equity Incentive Plan (the “2025 Plan”). The 2025 Plan was approved by the Company's Board of Directors (the "Board") on March 25, 2025, subject to stockholder approval, and became effective with such stockholder approval on May 7, 2025.

     

    The 2025 Plan provides for the issuance of up to 1,850,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”). Any shares of Common Stock subject to an award under the 2025 Plan, or to an award under the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) that was outstanding on May 7, 2025, that expires, is forfeited or cancelled, is settled for cash or otherwise does not result in the issuance of all of the shares subject to such award will, to the extent of such cancellation, forfeiture, expiration, cash settlement or non-issuance, become available for future awards under the 2025 Plan. Following the stockholders' approval of the 2025 Plan, no further awards will be granted under the 2016 Plan.

     

    Awards under the 2025 Plan may be granted to employees, consultants and advisors of the Company, as well as to the non-employee directors of the Company. Awards under the 2025 Plan can be granted in the form of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. The 2025 Plan will be administered by the Compensation and Organization Committee of the Company's Board.

     

    A description of the 2025 Plan was included in the Company’s proxy statement for its annual meeting of stockholders filed with the Securities and Exchange Commission on March 28, 2025. A copy of the 2025 Plan, the Form of Restricted Stock Unit Award Agreement (Executives) for use under the 2025 Plan, the Form of Restricted Stock Unit Award Agreement (Non-Employee Directors) for use under the 2025 Plan and the Form of Performance Stock Unit Agreement for use under the 2025 Plan are filed as Exhibit 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 5.07.Submission of Matters to a Vote of Security Holders

     

    On May 7, 2025, the Company held its 2025 Annual Meeting of Stockholders and the Company’s stockholders voted on the following matters:

     

    Election of Directors

     

    The following nominees were elected to serve as directors for a term that will last until the Company’s 2026 Annual Meeting of Stockholders or until his or her successor is duly elected and qualified. The number of votes cast for and withheld from each nominee and the number of broker non-votes with respect to each nominee were as follows:

     

    Name  Votes For   Votes Withheld   Broker Non-Votes 
    William W. Burke   15,557,077    436,231    3,037,240 
    Valerie L. Asbury   15,267,124    726,184    3,037,240 
    Sheri L. Dodd   15,796,147    197,161    3,037,240 
    Raymond O. Huggenberger   15,756,282    237,026    3,037,240 
    Laura G. King   15,862,873    130,435    3,037,240 
    D. Brent Shafer   14,929,921    1,063,387    3,037,240 
    Carmen B. Volkart   15,796,104    197,204    3,037,240 
    B. Vindell Washington   15,774,288    219,020    3,037,240 

     

     

     

     

    Ratification of the Selection of Grant Thornton LLP as the Company’s Independent Auditor for 2025

     

    The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 by voting as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    18,900,463   121,340    8,745    0 

     

    Advisory Vote on Approval of the Compensation of the Company’s Named Executive Officers

     

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by voting as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    15,658,844   321,637    12,827    3,037,240 

     

    Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of the Company’s Named Executive Officers

     

    The Company’s stockholders voted as follows on the frequency of future advisory votes on the compensation of the Company’s named executive officers:

     

    1 Year  2 Years   3 Years   Abstain   Broker Non-Votes 
    14,948,653   7,171    1,020,661    16,823    3,037,240 

     

    Based on these results, and consistent with the Board’s recommendation, the Board has determined that the Company will hold future advisory votes to approve the compensation of the Company’s named executive officers every year, until the next required vote on the frequency of future advisory votes on executive compensation.

     

    Approval of the Company’s 2025 Equity Incentive Plan

     

    The Company’s stockholders approved the Company’s 2025 Equity Incentive Plan by voting as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    15,286,584   697,589    9,135    3,037,240 

     

    Item 9.01.Financial Statements and Exhibits

     

    (d) Exhibits

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
         
    10.1   Tactile Systems Technology, Inc. 2025 Equity Incentive Plan.
    10.2   Form of Restricted Stock Unit Award Agreement (Executives) under the 2025 Equity Incentive Plan.
    10.3   Form of Restricted Stock Unit Award Agreement (Non-Employee Directors) under the 2025 Equity Incentive Plan.
    10.4   Form of Performance Stock Unit Agreement under the 2025 Equity Incentive Plan.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

      TACTILE SYSTEMS TECHNOLOGY, INC.
       
    Date: May 9, 2025 By: /s/ Elaine M. Birkemeyer
        Elaine M. Birkemeyer 
        Chief Financial Officer

     

     

     

    Get the next $TCMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TCMD

    DatePrice TargetRatingAnalyst
    1/5/2026$35.00Neutral → Overweight
    Piper Sandler
    11/4/2025$28.00Neutral → Buy
    BTIG Research
    10/3/2025$23.50Buy
    Lake Street
    5/6/2025$14.00Overweight → Neutral
    Piper Sandler
    2/19/2025$23.00 → $18.00Buy → Neutral
    B. Riley Securities
    11/5/2024Outperform → Perform
    Oppenheimer
    11/5/2024Buy → Neutral
    BTIG Research
    9/26/2024$23.00Buy
    B. Riley Securities
    More analyst ratings

    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Tactile Systems Technology Inc.

    3 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    3/11/26 4:13:02 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Director Pearson Andrea was granted 852 shares (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    3/11/26 4:13:53 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Dodd Sheri Louise sold $318,144 worth of shares (10,993 units at $28.94), decreasing direct ownership by 4% to 243,885 units (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    2/26/26 4:57:21 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM

    3/17/26 7:50:00 AM ET
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

    MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Andrea Pearson to the Company's Board of Directors ("Board") and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, market

    3/9/26 8:00:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    SEC Filings

    View All

    SEC Form PRE 14A filed by Tactile Systems Technology Inc.

    PRE 14A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

    3/10/26 9:01:02 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Systems Technology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

    3/9/26 8:06:19 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Tactile Systems Technology Inc.

    144 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    2/24/26 4:29:52 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tactile Systems upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Tactile Systems from Neutral to Overweight and set a new price target of $35.00

    1/5/26 8:37:29 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Systems upgraded by BTIG Research with a new price target

    BTIG Research upgraded Tactile Systems from Neutral to Buy and set a new price target of $28.00

    11/4/25 7:20:09 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Tactile Systems with a new price target

    Lake Street initiated coverage of Tactile Systems with a rating of Buy and set a new price target of $23.50

    10/3/25 8:49:24 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

    MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Andrea Pearson to the Company's Board of Directors ("Board") and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, market

    3/9/26 8:00:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical Appoints Laura King to Board of Directors

    MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE

    1/13/25 8:00:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Financials

    Live finance-specific insights

    View All

    Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 millionGross margin of 78% versus 75% in Q4 2024Net income of $10.6 million versus $9.7 million in Q4 2024Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 millionGross margin of 76%, compared to 74% in 2024Oper

    2/17/26 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

    MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that it has acquired LymphaTech Inc., for an upfront cash payment at closing of $6.8 million, plus potential additional consideration that is contingent upon the achievement of future milestones. Founded in 2014, LymphaTech, Inc. is a privately held medical technology company pioneering a digital, three-dimensional ("3D") full body measurement and monitoring platform designed specifically for lymphedema. Damage to the lymphatic system from chronic fluid accumulat

    2/17/26 4:04:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026

    MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2025 financial results will be released after the market closes on Tuesday, February 17, 2026. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 17, 2026, to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13758303. A live webcast of the call

    2/3/26 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

    SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 7:29:11 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 5:04:27 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/8/24 3:21:42 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care